RUBEN ANDUJAR ESPINOSA

@universidad de murcia

Medicicne / Medicine
Health Science Associated Proffesor

RUBEN ANDUJAR ESPINOSA


               Download Compact PDF  
https://researchid.co/rubemed

RESEARCH, TEACHING, or OTHER INTERESTS

Pulmonary and Respiratory Medicine, Immunology and Allergy
26

Scopus Publications

1904

Scholar Citations

22

Scholar h-index

24

Scholar i10-index

Scopus Publications

  • The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis
    Ismael García-Moguel, Álvaro Martínez-Mesa, Rubén Andújar-Espinosa, Rocío Díaz-Campos, José Luis Velasco-Garrido, Jose Luis Sanchez-Trincado, Elisa Luzon, Javier Nuevo, Carlos Alconada, Miguel Ángel Gutiérrez, Gabriel Niza, Alicia Padilla-Galo
    Respiratory Medicine, 2025
    BACKGROUND: The ORBE II study showed the real-world effectiveness of benralizumab in severe eosinophilic asthma (SEA). This subgroup analysis aimed to characterize patients and outcomes based on baseline blood eosinophil count (BEC) and/or fractional exhaled nitric oxide (FeNO) levels. METHODS: In this analysis of the ORBE II retrospective study, SEA patients receiving benralizumab were categorized into subgroups based on individual or combined BEC/FeNO levels, according to the following thresholds: high BEC (hiBEC): ≥300 cells/μL; low BEC (loBEC): <300 cells/μL; high FeNO (hiFeNO): ≥50 ppb; low FeNO (loFeNO): <50 ppb. Baseline and up to 1 year of follow-up data are described. RESULTS: Most patients with available data were classified as hiBEC (72.6 %) and 38.3 % as hiFeNO. The distribution according to combined baseline BEC and FeNO levels revealed a heterogeneous patient population. Although common SEA features were shared among subgroups, some distinct characteristics were observed, including elevated allergic asthma prevalence in hiBEC/loFeNO patients, high obesity prevalence and fewer non-smokers in loBEC/loFeNO patients, remarkable severe exacerbation rates in loBEC/hiFeNO patients [5.5 SD (6.0)], and more severe symptoms in the hiBEC/loBEC subgroup. All subgroups showed benefits following benralizumab treatment, with super-responder rates ranging from 68.2 % to 83.3 % and clinical remission rates reaching 70.0 %. Particularly good responses were noted in hiBEC/hiFeNO patients. CONCLUSIONS: This study shows the variability of T2 biomarkers in ORBE II SEA patients, emphasizing the prevalence of high BEC values. While benralizumab benefits were important regardless of BEC, high BEC predicted good outcomes and FeNO had less influence on treatment effectiveness.
  • Tezepelumab in Patients With Severe Asthma: Response at 3 Months
    JC Miralles-López, R Andújar-Espinosa, FJ Bravo-Gutierrez, S Cabrejos-Perotti, M Ramírez-Hernández, C Díaz-Chantar, MJ Pajarón Fernández, J Valverde-Molina, V Pérez-Fernández, and
    Journal of Investigational Allergology and Clinical Immunology, 2025
  • Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice
    Juan-Carlos Miralles-López, Yulia Petryk-Petryk, Juan José Cortés-Collado, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Sheila Cabrejos-Perotti, José Valverde-Molina, Virginia Pérez-Fernández, RE-ASGRAMUR RE-ASGRAMUR GROUP
    Allergologia Et Immunopathologia, 2025
    Introduction: Tezepelumab is a human monoclonal immunoglobulin G2λ antibody that targets the cytokine thymic stromal lymphopoietin (TSLP). In clinical trials, tezepelumab has been shown to reduce the annualized asthma exacerbation rate in patients with both high and low levels of T2 inflammation biomarkers. Methods: This is a prospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) conducted under routine clinical practice conditions. We analyzed exacerbations, changes in lung function (pre-bronchodilator FEV1), asthma control (ACT), and quality of life (mini AQLQ). In addition, T2 biomarkers, including blood eosinophils and exhaled nitric oxide (FeNO), were analyzed. Results: We present a series of 38 patients with severe allergic asthma who received treatment with tezepelumab. More than half of these patients had previously shown inadequate responses to other biologic therapies. Following treatment, the annualized rate of exacerbations decreased markedly from a baseline mean of 2.2 to 0.28, representing an 86.8% reduction. The Asthma Control Test (ACT) score improved by an average of 5.2 points, while the mini Asthma Quality of Life Questionnaire (miniAQLQ) score increased by 1 point. Pulmonary function also improved significantly, with a mean increase of 170 mL in FEV1. Furthermore, type 2 inflammatory biomarkers, including blood eosinophil counts and fractional exhaled nitric oxide (FeNO), showed a significant reduction. Conclusions: Tezepelumab is an effective treatment for severe allergic asthma, improving exacerbations, disease control, quality of life, and lung function.
  • Real-life effectiveness of tezepelumab in severe asthma
    Juan Carlos Miralles-López, Francisco-José Bravo-Gutierrez, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, Cayetano Díaz-Chantar, Mercedes Ramírez-Hernández, Sheila Cabrejos-Perotti, Maria Jesús Avilés-Inglés, Inmaculada Ibarra-Calabuig, Miguel Henrique Reyes-Cotes, Manuel José Pajarón-Fernández, Roberto Bernabéu-Mora, Consuelo Alcalde-Rumayor, María Loreto Alemany-Francés, José Valverde-Molina, Virginia Pérez-Fernández, RE-ASGRAMUR GROUP
    Allergologia Et Immunopathologia, 2025
    Background: Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes. Methods: This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions. Results: We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a mean annualized rate of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable. Conclusions: Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.
  • Persons With Chronic Obstructive Pulmonary Disease and High Levels of Activation Improved Their Physical Activity Skills After an Educational Session
    María C. Fernández-Sánchez, Francisco J. Ruiz-López, José A. Ros-Lucas, Rubén Andújar-Espinosa, Juan Del Coso, Teresa García-Pastor
    Chronic Obstructive Pulmonary Diseases, 2024
    Background: Daily physical activity is part of the self-management of patients with chronic obstructive pulmonary disease (COPD), and didactic information sessions may be insufficient for the provision of these skills. Prior activation can determine sensitivity to these sessions. We evaluated whether the activation in patients with COPD, as measured by the Patient Activation Measure (PAM)-13 questionnaire, determined their responses to an educational group session on physical activity (PA), which were measured with actigraphy by the number of steps/day. Methods: We conducted an uncontrolled clinical trial in an outpatient clinic with 75 patients with nonexacerbating COPD (forced expiratory volume in 1 second 30%-80%) who were selected consecutively. Patients were provided with an actigraph that they used for 15 days and completed the PAM-13 questionnaire. On the eighth day, they attended a group educational session where they were given PA information. We compared the changes in activity after the session by pooled PAM levels and the correlation between the change in the number of steps/day and the PAM-13 questionnaire. Results: <0.05). Conclusion: COPD patients with greater activation showed greater improvements in daily PA after a group educational session.
  • Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study
    Francisco Javier Bravo-Gutiérrez, Juan Carlos Miralles-López, José Valverde-Molina, María Loreto Alemany Francés, Rubén Andújar-Espinosa, Manuel Castilla-Martínez, María Jesús Avilés-Inglés, Ana Mora-González, Manuel José Pajarón-Fernández, Sheila Cabrejos-Perotti, José Meseguer-Arce, Isabel Flores Martín, Virginia Pérez-Fernández, and
    International Archives of Allergy and Immunology, 2024
    &lt;b&gt;&lt;i&gt;Introduction:&lt;/i&gt;&lt;/b&gt; Asthma is one of the most common chronic diseases and affects around 334 million people worldwide. The estimated prevalence of severe asthma is 3–10% of the asthmatic population. Mepolizumab has demonstrated efficacy in reducing exacerbations, oral corticosteroid use, and improving quality of life, asthma control, and lung function in patients with severe eosinophilic asthma (SEA). Our study aimed to check the response to mepolizumab in a series of severe asthma patients regarding exacerbations, oral corticosteroid use, asthma control, quality of life, and lung function and to compare the response between patients with and without nasal polyps. &lt;b&gt;&lt;i&gt;Method:&lt;/i&gt;&lt;/b&gt; This is a retrospective, multicenter study of RE-ASGRAMUR (Register of Severe Asthma of the Region of Murcia) performed in eight hospitals of the Region of Murcia (Spain) under routine clinical practice conditions. We included patients diagnosed with SEA who completed at least 1 year of treatment with mepolizumab. We analyzed clinical characteristics, drug tolerance, and effectiveness: exacerbations, ACT, miniAQLQ, forced expiratory volume in 1 s (FEV1), and use of oral corticosteroids. We also compared the results between patients with and without nasal polyps. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; The median of exacerbations before treatment was 3 and decreased to 0 after treatment (mean decrease of 77.4%). The median diary oral prednisone intake was 15 mg before treatment and 5 mg after treatment (mean 56% reduction). We have obtained a significant improvement in other variables: ED visits and hospitalizations, asthma control (ACT), quality of life (miniAQLQ), and lung function (FEV1). Thirty-four out of 70 patients (48.57%) fulfilled the criteria of super-responder, and 17 out of 70 (24.29%) had a complete response. More patients in the group with nasal polyps fulfilled the criteria of super-responder and complete response to mepolizumab. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Mepolizumab is a safe and effective treatment for SEA patients, improving exacerbations, oral corticosteroid intake, asthma control, quality of life, and lung function. In patients with associated nasal polyposis, there is a statistically significant higher proportion of super-responders and complete responders.
  • Disease Modification in Asthma: Are We on the Right Way? A Multidisciplinary Expert Delphi Consensus (MODIASTHMA Consensus)
    Juan Carlos Miralles-López, Francisco Alvarez-Gutiérrez, Julio Delgado-Romero, Santiago Quirce, Jose Gregorio Soto-Campos, Ruben Andújar-Espinosa, Sheila Cabrejos-Perotti, Manuel Castilla-Martínez, Isabel Flores-Martín, Manuel José Pajarón-Fernández, José Valverde-Molina
    Journal of Asthma and Allergy, 2024
    Purpose: With the advent of biological therapies, emerging concepts regarding establishing new targets in asthma management, such as disease modification, have entered the debate among the scientific community. The definitions that form the conceptual basis of this goal need to be agreed upon. Methods: A multidisciplinary expert group was assembled as the steering committee. A systematic literature review was conducted to identify the scientific background for constructing appropriate definitions. Based on the literature review and the clinical experience of the experts, the committee built a list of statements that could be applied to establish the definition of disease modification in asthma. After that, a Delphi validation was performed to assess the appropriateness of the list of statements. The questionnaire included a total of 22 statements, divided into "Essential criteria for disease modification in asthma" (5 statements) and "Disease modification indicators and other considerations" (17 statements). Panelists used a 9-point Likert scale to measure agreement on each statement. The cut-off point for high consensus was defined as a minimum score of 7 and had to be reached by at least two-thirds of the experts. Results: A total of 192 asthma experts voted on statements anonymously. Of those, 104 (54%) were Pneumologists, 65 (34%) were allergologists, and 23 (12%) were Pediatricians. An interim analysis of round 1 data was performed. All statements reached consensus on the first round, with a median score above 7 in all cases. Conclusion: In conclusion, in this Delphi study, a large number of experts in the management of severe asthma from different specialties agreed on the clinical-functional and pathophysiological aspects to be considered in order to try to achieve disease modification.
  • Therapeutic Goals and Treatable Traits: Long-Term Trends in a Severe Asthma Population
    Carlos Almonacid-Sánchez, Borja G. Cosío, Andrea Trisán-Alonso, Francisco Javier Callejas-González, Carolina Cisneros, Eva Martínez-Moragón, Vicente Plaza Moral, Elisabeth Vera, José Gregorio Soto-Campos, Carlos Martínez-Rivera, Bernardino Alcazar-Navarrete, Isabel Urrutia Landa, Juan Luis García-Rivero, Alicia Padilla Galo, Francisco Álvarez-Gutierrez, Jacinto Ramos-González, José Ángel Carretero-Gracia, Inmaculada Lluch, Luis Puente, Rubén Andujar-Espinosa, Luis Pérez-de-Llano
    Archivos De Bronconeumologia, 2023
  • Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study
    Alicia Padilla-Galo, Isabel Moya Carmona, Pilar Ausín, Luis Carazo Fernández, Ismael García-Moguel, José Luis Velasco-Garrido, Rubén Andújar-Espinosa, Francisco Casas-Maldonado, Eva Martínez-Moragón, Carlos Martínez Rivera, Elisabet Vera Solsona, Fernando Sánchez-Toril López, Andrea Trisán Alonso, Marina Blanco Aparicio, Marcela Valverde-Monge, Borja Valencia Azcona, Marta Palop Cervera, Javier Nuevo, Jesús Sánchez Tena, Gustavo Resler, Elisa Luzón, Alberto Levy Naon
    Respiratory Research, 2023
    Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adult SEA patients who had been prescribed benralizumab. Demographic and clinical data of 204 SEA patients were collected 12 months prior to benralizumab initiation (baseline) and at follow-up. Exacerbation rate, asthma symptoms, maintenance oral corticosteroid (OCS) use and lung function were evaluated, among other variables. Results A total of 204 SEA patients were evaluated. Mean (standard deviation, SD) age of the study population was 56.4 (12.4) years, 62.3% were women and mean (SD) duration of asthma was 15.1 (12.7) years. Median (Q1–Q3) follow-up duration was 19.5 (14.2–24.2) months. At baseline, 72.6% of the overall population (OP) presented blood eosinophil counts ≥ 300 cells/µL; 36.8% had comorbid chronic rhinosinusitis with nasal polyps (CRSwNP); 84.8% reported at least one severe exacerbation, and 29.1% were OCS-dependent. At 1 year of follow-up, patients receiving benralizumab treatment had a 85.6% mean reduction in exacerbations from baseline, and 81.4% of patients achieved zero exacerbations. We also found a clinically relevant mean (SD) increase in pre-bronchodilator (BD) FEV1 of 331 (413) mL, with 66.7% of patients achieving a pre-BD FEV1 increase ≥ 100 mL, and 46.3% of patients achieving a pre-BD FEV1 ≥ 80% of predicted. Regarding symptom control, 73.8% of the OP obtained an ACT score ≥ 20 points. After 1 year of follow-up, mean reduction in the daily OCS dose was 70.5%, and complete OCS withdrawal was achieved by 52.8% of the OCS-dependent patients. Almost half (43.7%) of the OP on benralizumab met all four criteria for clinical remission. Patients with concomitant CRSwNP obtained similar or enhanced outcomes. Conclusions These data support the real-world benefits of benralizumab in SEA patients, and particularly in those with concomitant CRSwNP. Trial registration NCT04648839.
  • Calcifediol in the management of vitamin D deficiency-related skeletal and extraskeletal diseases: overview and clinical cases
    Enrique Casado, Ester Costa, Pedro Mezquita-Raya, Rubén Andújar-Espinosa, José Luis Neyro
    Drugs in Context, 2023
    ) has recently become more widely available. Calcifediol is one step closer than cholecalciferol in the metabolic pathway to biologically active vitamin D. Pharmacokinetic differences between these vitamin D metabolites confer putative advantages for calcifediol in certain clinical situations. The clinical use of calcifediol is explored more closely through case studies, which illustrate its adjunctive role in the treatment of several vitamin D deficiency-related skeletal and extraskeletal diseases.
  • Early Effectiveness of Dupilumab in Patients With Type 2 Severe Asthma: A Prospective Real-Life Study
    , M Castilla-Martínez, R Andújar-Espinosa, I Flores-Martín, MH Reyes Cotes, S Cabrejos-Perotti, JC Miralles-López, A Carbonell-Martínez, FJ Bravo-Gutierrez, J Valverde-Molina, V Pérez-Fernández
    Journal of Investigational Allergology and Clinical Immunology, 2023
  • CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia
    José Antonio Ros-Lucas, Domingo Andrés Pascual-Figal, José Antonio Noguera-Velasco, Álvaro Hernández-Vicente, Iria Cebreiros-López, María Arnaldos-Carrillo, Isabel M. Martínez-Ardil, Elisa García-Vázquez, Mario Aparicio-Vicente, Elena Solana-Martínez, Sheyla Yolany Ruiz-Martínez, Laura Fernández-Mula, Rubén Andujar-Espinosa, Beatriz Fernández-Suarez, Maria Dolores Sánchez-Caro, Carlos Peñalver-Mellado, Francisco José Ruiz-López
    Scientific Reports, 2022
  • Calcifediol for Use in Treatment of Respiratory Disease
    Marta Entrenas-Castillo, Lourdes Salinero-González, Luis M. Entrenas-Costa, Rubén Andújar-Espinosa
    Nutrients, 2022
  • [Translated article] FEV1/FVC Cut-off Values for the Diagnosis of Airflow Obstruction in Pediatric Patients: The Pediatric Airflow Obstruction (PAO) Study
    Chunshao Hu-Yang, Virginia Perez-Fernandez, Ada Luz Andreu Rodríguez, Rubén Andújar Espinosa, José Valverde-Molina
    Archivos De Bronconeumologia, 2022
  • Effectiveness of Benralizumab in Severe Eosinophilic Asthma Under Conditions of Routine Clinical Practice
    JC Miralles López, R Andújar-Espinosa, FJ Bravo-Gutiérrez, M Castilla-Martínez, I Flores-Martín, ML Alemany-Francés, MJ Pajarón-Fernández, A Mora González, J Valverde-Molina, V Pérez-Fernández
    Journal of Investigational Allergology and Clinical Immunology, 2022
  • Analysis of response of severe eosinophilic asthmatic patients to benralizumab
    Juan Carlos Miralles-López, Rubén Andújar-Espinosa, Francisco Javier Bravo-Gutiérrez, Manuel Castilla-Martínez, Isabel Flores-Martín, María Loreto Alemany-Francés, Manuel José Pajarón-Fernández, Ana Mora-González, Sheila Cabrejos-Perotti, Zouhair El-Molaka, José Meseguer-Arce, María Jesús Avilés-Inglés, José Valverde-Molina, Virginia Pérez-Fernández, RE-ASGRAMUR GROUP
    Allergologia Et Immunopathologia, 2022
  • Vitamin D Supplementation: A Treatment With Possible Benefits in Asthma
    Rubén Andújar-Espinosa, Lourdes Salinero-González
    Archivos De Bronconeumologia, 2021
  • Influence of vitamin D supplementation on the quality of life of asthma patients: Findings from ACVID randomised clinical trial
    R. Andújar-Espinosa, M. Aparicio-Vicente, F.J. Ruiz-López, L. Salinero-González
    Respiratory Medicine, 2021
  • Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: The ACVID randomised clinical trial
    Rubén Andújar-Espinosa, Lourdes Salinero-González, Fátima Illán-Gómez, Manuel Castilla-Martínez, Chunshao Hu-Yang, Francisco José Ruiz-López
    Thorax, 2021
  • Protective hood prototype for bronchoscopy during Covid-19
    Rubén Andújar-Espinosa, Jose Antonio Ros-Lucas, Francisco José Ruiz-López
    Medicina Clinica, 2021
  • Pneumonia associated with intrabronchial foreign body
    R. Andújar-Espinosa, J.A. Ros-Lucas, F.J. Ruiz-López
    Revista Clinica Espanola, 2020
  • Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
    Luis Pérez de Llano, Eva Martínez-Moragón, Vicente Plaza Moral, Andrea Trisan Alonso, Carlos Almonacid Sánchez, Francisco Javier Callejas, Elisabeth Vera, Jose Gregorio Soto Campos, Carlos Martinez Rivera, Bernardino Alcázar Navarrete, Isabel Urrutia Landa, Juan Luis Garcia Rivero, Alicia Padilla Galo, Francisco Alvarez Gutierrez, Pedro Landete, Jacinto Ramos González, Cleofé Fernández Aracil, José Ángel Carretero Gracia, Inmaculada Lluch, Luis Puente, Ruben Andujar-Espinosa, Borja Garcia Cosío
    Respiratory Medicine, 2019
  • Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma
    Astrid Crespo-Lessmann, Vicente Plaza, Francisco-Javier González-Barcala, Toni Fernández-Sánchez, Joaquín Sastre
    BMJ Open Respiratory Research, 2017
  • Efficacy of a self-management plan in exacerbations for patients with advanced COPD
    Roberto Bernabeu-Mora, Juan Miguel Sánchez-Nieto, Rubén Andújar-Espinosa, Chunshao Hu, Beatriz Gálvez-Martínez, Andrés Carrillo-Alcaraz, Carlos Federico Álvarez-Miranda, Olga Meca-Birlanga, Eva Abad-Corpa
    International Journal of Copd, 2016
  • Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients
    Vicente Plaza, Concepción Fernández-Rodríguez, Carlos Melero, Borja G. Cosío, Luís Manuel Entrenas, Luis Pérez de Llano, Fernando Gutiérrez-Pereyra, Eduard Tarragona, Rosa Palomino, Antolín López-Viña, and
    Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016
  • High eosinophil levels and poor evolution in occupational asthma due to cyanoacrylate exposure
    Ruben Andujar, María‐Jesús Cruz, Ana Villar, Ferran Morell, Xavier Muñoz
    American Journal of Industrial Medicine, 2011

RECENT SCHOLAR PUBLICATIONS

  • Real-life efficacy of Tezepelumab in patients with failure to other biologic drugs
    JC Miralles-López, JJC Collado, YP Petryk, FJ Bravo-Gutierrez, ...
    European annals of allergy and clinical immunology , 2025
    2025
    Citations: 1
  • Efficacy of tezepelumab in patients with severe allergic asthma in clinical practice
    JC Miralles-López, Y Petryk-Petryk, JJ Cortés-Collado, FJ Bravo-Gutierrez, ...
    Allergologia et Immunopathologia 53 (5), 193-196 , 2025
    2025
    Citations: 1
  • Early and sustained clinical benefits of benralizumab in severe eosinophilic asthma: findings from the ORBE II Study
    P Ausín, ME Navarrete-Rouco, L Carazo, JL Sanchez-Trincado, E Luzon, ...
    Journal of Clinical Medicine 14 (9), 3011 , 2025
    2025
    Citations: 2
  • Real-life effectiveness of tezepelumab in severe asthma
    JC Miralles-López, FJ Bravo-Gutierrez, R Andújar-Espinosa, ...
    Allergologia et Immunopathologia 53 (2), 169-173 , 2025
    2025
    Citations: 17
  • The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis
    I García-Moguel, Á Martínez-Mesa, R Andújar-Espinosa, R Díaz-Campos, ...
    Respiratory Medicine 237, 107940 , 2025
    2025
    Citations: 7
  • Tezepelumab in patients with severe asthma: response at 3 months
    C Lucía
    J Investig Allergol Clin Immunol 35 (2), 130-139 , 2025
    2025
    Citations: 7
  • Disease modification in asthma: are we on the right way? A multidisciplinary expert Delphi consensus (MODIASTHMA Consensus)
    JC Miralles-López, FJ Alvarez-Gutiérrez, J Delgado-Romero, S Quirce, ...
    Journal of Asthma and Allergy, 1163-1171 , 2024
    2024
    Citations: 4
  • Burden of uncontrolled severe asthma with and without elevated type-2 inflammatory biomarkers
    B Ding, S Chen, E Rapsomaniki, A Quinton, W Cook, HK Reddel, A Papi, ...
    The Journal of Allergy and Clinical Immunology: In Practice 12 (4), 970-982 , 2024
    2024
    Citations: 23
  • Persons with chronic obstructive pulmonary disease and high levels of activation improved their physical activity skills after an educational session
    MC Fernández-Sánchez, FJ Ruiz-López, JA Ros-Lucas, ...
    Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation 11 (3 … , 2024
    2024
    Citations: 1
  • Effectiveness of mepolizumab in patients with severe eosinophilic asthma with/without nasal polyposis: a real-life study
    FJ Bravo-Gutierrez, JC Miralles-Lopez, J Valverde-Molina, ...
    International Archives of Allergy and Immunology 185 (3), 253-259 , 2024
    2024
    Citations: 8
  • Early response to dupilumab in patients with and without previous biologic treatment
    JC Miralles, J Valverde-Molina, M Castilla-Martinez, R Andujar-Espinosa, ...
    ALLERGY 78 , 2023
    2023
  • Therapeutic goals and treatable traits: long-term trends in a severe asthma population
    C Almonacid-Sánchez, BG Cosío, A Trisán-Alonso, FJ Callejas-González, ...
    Archivos de bronconeumologia 59 (12), 842-845 , 2023
    2023
    Citations: 1
  • ORBE II study: clinical characteristics and outcomes after treatment with benralizumab according to baseline blood eosinophil count
    AM Mesa, JLV Garrido, IG Moguel, C Martinez, R Andujar, C Cañete, ...
    European Respiratory Journal 62 (suppl 67) , 2023
    2023
  • Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study
    A Padilla-Galo, I Moya Carmona, P Ausín, L Carazo Fernández, ...
    Respiratory Research 24 (1), 235 , 2023
    2023
    Citations: 56
  • Calcifediol in the management of vitamin D deficiency-related skeletal and extraskeletal diseases: overview and clinical cases
    E Casado, E Costa, P Mezquita-Raya, R Andújar-Espinosa, JL Neyro
    Drugs in Context 12 , 2023
    2023
    Citations: 6
  • Cluster analyses from the real-world NOVELTY study: six clusters across the asthma-COPD spectrum
    R Hughes, E Rapsomaniki, AT Bansal, J Vestbo, D Price, A Agustí, ...
    The Journal of Allergy and Clinical Immunology: In Practice 11 (9), 2803-2811 , 2023
    2023
    Citations: 9
  • Early effectiveness of dupilumab in patients with type 2 severe asthma: A prospective real-life study
    M Castilla-Martínez, R Andújar-Espinosa, I Flores-Martín, MHR Cotes, ...
    Journal of investigational allergology & clinical immunology 33 (2), 126-128 , 2023
    2023
    Citations: 4
  • Early effectivity of dupilumab in patients with t2 severe asthma: a prospective real-life study
    JCM López
    J Investig Allergol Clin Immunol 33 (4) , 2023
    2023
  • Dupilumab y su efectividad en el control de crisis y mejora de la calidad de vida en una unidad de asma grave
    LF Mula, RA Espinosa, MF Granja, JL Martínez, EM Orenes, ...
    Revista española de patología torácica 35 (1), 8-9 , 2023
    2023
  • Utilidad del biomarcador ca 15-3 como predictor pronóstico en pacientes con neumonía por COVID-19
    MF Granja, JAR Lucas, LF Mula, JL Martínez, EM Orenes, SYR Martínez, ...
    Revista española de patología torácica 35 (1), 88-89 , 2023
    2023

MOST CITED SCHOLAR PUBLICATIONS

  • Validation of the ‘Test of the Adherence to Inhalers’(TAI) for asthma and COPD patients
    V Plaza, C Fernández-Rodríguez, C Melero, BG Cosío, LM Entrenas, ...
    Journal of aerosol medicine and pulmonary drug delivery 29 (2), 142-152 , 2016
    2016
    Citations: 412
  • Clinical audit of COPD patients requiring hospital admissions in Spain: AUDIPOC study
    F Pozo-Rodriguez, JL López-Campos, CJ Alvarez-Martinez, ...
    Public Library of Science 7 (7), e42156 , 2012
    2012
    Citations: 164
  • Anxiety, depression, and asthma control: changes after standardized treatment
    J Sastre, A Crespo, A Fernandez-Sanchez, M Rial, V Plaza, FC González, ...
    The Journal of Allergy and Clinical Immunology: In Practice 6 (6), 1953-1959 , 2018
    2018
    Citations: 137
  • Factors associated with depression and severe depression in patients with COPD
    M Miravitlles, J Molina, JA Quintano, A Campuzano, J Pérez, C Roncero, ...
    Respiratory Medicine 108 (11), 1615-1625 , 2014
    2014
    Citations: 122
  • Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort
    HK Reddel, J Vestbo, A Agustí, GP Anderson, AT Bansal, R Beasley, ...
    European Respiratory Journal 58 (3) , 2021
    2021
    Citations: 97
  • Treatable traits in the NOVELTY study
    A Agustí, E Rapsomaniki, R Beasley, R Hughes, H Müllerová, A Papi, ...
    Respirology 27 (11), 929-940 , 2022
    2022
    Citations: 87
  • Mixed Th2 and non-Th2 inflammatory pattern in the asthma–COPD overlap: a network approach
    LP de Llano, BG Cosío, A Iglesias, N de Las Cuevas, JJ Soler-Cataluña, ...
    International journal of chronic obstructive pulmonary disease, 591-601 , 2018
    2018
    Citations: 74
  • Cognitive status among patients with chronic obstructive pulmonary disease
    C Roncero, AI Campuzano, JA Quintano, J Molina, J Perez, M Miravitlles
    International Journal of Chronic Obstructive Pulmonary Disease, 543-551 , 2016
    2016
    Citations: 65
  • Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study
    R Hughes, E Rapsomaniki, C Janson, C Keen, BJ Make, PR Burgel, ...
    Respiratory medicine 200, 106921 , 2022
    2022
    Citations: 57
  • Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study
    A Padilla-Galo, I Moya Carmona, P Ausín, L Carazo Fernández, ...
    Respiratory Research 24 (1), 235 , 2023
    2023
    Citations: 56
  • Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study
    LP de Llano, E Martínez-Moragón, VP Moral, AT Alonso, CA Sánchez, ...
    Respiratory Medicine 151, 49-54 , 2019
    2019
    Citations: 54
  • Effect of vitamin D supplementation on asthma control in patients with vitamin D deficiency: the ACVID randomised clinical trial
    R Andújar-Espinosa, L Salinero-González, F Illán-Gómez, ...
    Thorax 76 (2), 126-133 , 2021
    2021
    Citations: 53
  • Documento de consenso de asma grave en adultos. Actualización 2020
    FJ Álvarez-Gutiérrez, M Blanco-Aparicio, V Plaza, C Cisneros, ...
    Open Respiratory Archives 2 (3), 158-174 , 2020
    2020
    Citations: 46
  • Medical care according to risk level and adaptation to Spanish COPD Guidelines (Gesepoc): the Epoconsul Study
    MC Rubio, JLR Hermosa, JJ Soler-Cataluña, JL López-Campos, ...
    Archivos de Bronconeumología (English Edition) 54 (5), 270-279 , 2018
    2018
    Citations: 45
  • Efficacy of a self-management plan in exacerbations for patients with advanced COPD
    JM Sánchez-Nieto, R Andujar-Espinosa, R Bernabeu-Mora, C Hu, ...
    International journal of chronic obstructive pulmonary disease, 1939-1947 , 2016
    2016
    Citations: 45
  • Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate–severe asthma
    A Crespo-Lessmann, V Plaza, FJ González-Barcala, ...
    BMJ open respiratory research 4 (1) , 2017
    2017
    Citations: 42
  • Eosinophilic COPD patients display a distinctive serum miRNA profile from asthma and non-eosinophilic COPD
    VJ Asensio, A Tomás, A Iglesias, LP de Llano, V Del Pozo, BG Cosío, ...
    Archivos de Bronconeumología (English Edition) 56 (4), 234-241 , 2020
    2020
    Citations: 35
  • Variability in adherence to clinical practice guidelines and recommendations in COPD outpatients: a multi-level, cross-sectional analysis of the EPOCONSUL study
    M Calle Rubio, JL López-Campos, JJ Soler-Cataluña, ...
    Respiratory Research 18 (1), 200 , 2017
    2017
    Citations: 35
  • Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores
    M Miravitlles, J Molina, JA Quintano, A Campuzano, J Pérez, C Roncero, ...
    International Journal of Chronic Obstructive Pulmonary Disease, 823-831 , 2018
    2018
    Citations: 29
  • The burden of mild asthma: clinical burden and healthcare resource utilisation in the NOVELTY study
    SM Golam, C Janson, R Beasley, JM FitzGerald, T Harrison, B Chipps, ...
    Respiratory medicine 200, 106863 , 2022
    2022
    Citations: 28